Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2017-04-26 Director's Dealing
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
NOTYFIKACJA
Director's Dealing Classification · 99% confidence The document is titled "Powiadomienie o transakcji/transakcjach*, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of transaction(s) referred to in Article 19(1) of the MAR Regulation). It details the purchase ('Kupno') of shares ('akcje zwykłe na okaziciela') by an entity ('Glatton Spółka z ograniczoną odpowiedzialnością') closely associated with a member of the Management Board ('Osoba blisko związana z Prezesem Zarządu Spółki Celon Pharma S.A. Panem Maciejem Wieczorkiem'). This structure—reporting personal share transactions by directors or closely related persons—directly corresponds to the definition of Director's Dealing reports, which are mandated under MAR Article 19. The corresponding code is DIRS.
2017-04-26 Polish
Powiadomienie o transakcjach osoby blisko związanej z osobą pełniącą obowiązki zarządcze - Content (PL)
Director's Dealing Classification · 95% confidence The document text is very short (286 characters) and explicitly states that the management board received a notification regarding transactions involving the company's shares from a person closely associated with the CEO. It concludes by stating that the content of the notification is attached as an appendix ('Treść powiadomieniastanowi załącznik do niniejszego raportu'). This structure—a brief announcement referencing an attached document detailing insider transactions—strongly suggests a Director's Dealing report (DIRS) or, given the brevity and reference to an attachment, potentially a Report Publication Announcement (RPA) if the core content is the attached document. However, the subject matter is clearly about transactions by a person closely related to management, which aligns perfectly with the definition of Director's Dealing (DIRS). Since the text itself is the announcement of the transaction details being attached, it could also be RPA, but DIRS is more specific to the content being announced. Given the specific nature of the content (insider transaction notification), DIRS is the most appropriate primary classification, even if it's a short announcement of the filing.
2017-04-26 Polish
Zmiana terminu publikacji raportu za I kwartał 2017 r. - Content (PL)
Report Publication Announcement Classification · 99% confidence The document text is very short (338 characters) and explicitly states that the company (Zarząd Celon Pharma S.A.) is informing about a *change in the date* for releasing the quarterly report for Q1 2017. It announces *when* the report will be published (May 26, 2017), referencing a previous announcement. This is not the report itself (which would be an IR), but an announcement about the publication schedule of a report. This fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports.
2017-04-25 Polish
CELON_Dodatkowe_noty_objasniajace.pdf
Annual Report Classification · 95% confidence The document contains detailed financial notes, tables of comparative financial data (2015 vs 2016), information on accounting policies, remuneration, and legal proceedings. It is clearly a section of a comprehensive financial report (likely the 'Additional Notes' or 'Notes to the Financial Statements' section of an Annual Report). Since it provides substantive financial data and analysis for a specific fiscal period, it falls under the category of an Interim/Quarterly or Annual Report. Given the depth and the nature of the disclosures (e.g., audit fees, detailed investment tables), it is classified as an Annual Report (10-K) equivalent. FY 2016
2017-04-20 Polish
CELON_Opisana_roznica_w_zmianie_stanu_rezerw.pdf
Interim / Quarterly Report Classification · 95% confidence The document contains specific financial data tables detailing cash flow structures, reserve changes, and cash equivalents for the years 2015 and 2016. It provides substantive financial data rather than just an announcement or certification. As it represents a component of a comprehensive financial report (specifically the cash flow statement section), it falls under the category of an Interim/Quarterly Report or a component of a full financial report, which is best classified as IR. FY 2016
2017-04-20 Polish
CELON_Sposob_obliczenia_zysku_na_1_akcje.pdf
Interim / Quarterly Report Classification · 95% confidence The document contains specific financial data tables detailing net profit, weighted average number of shares, and earnings per share for the years 2016 and 2015. It also includes a breakdown of the calculation for the weighted average number of shares. Since it provides substantive financial data and analysis for a specific period rather than just an announcement or a summary, it qualifies as an Interim/Quarterly Report (IR). FY 2016
2017-04-20 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.